The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Brigham and Women's Hospital
- Enrollment
- 23
- Locations
- 1
- Primary Endpoint
- Serum aldosterone after angiotensin II infusion
Study Overview
Brief Summary
The purpose of this research protocol is to determine if the same effects are observed in vivo in humans using a similar approach. Demonstrating that mineralocorticoid acts on zona glomerulosa cells to regulate aldosterone production in a short feedback loop would provide important insight into hormone regulation, and explain variability in pathophysiologic states such as hypertension and cardiovascular diseases.
Detailed Description
In order to provide additional evidence indicating the presence of functional and in order to provide additional evidence indicating the presence of functional mineralocorticoid receptors (MR) on zona glomerulosa (ZG) cells, the investigators propose the following protocol in healthy volunteers. The investigators will evaluate aldosterone and cortisol production in response to an angiotensin II infusion after three separate test conditions: 1) placebo, 2) following a single dose of fludrocortisone, and 3) following a single dose of eplerenone (a MR antagonist).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Other
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 40 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Participants must be healthy, with no prior history of hypertension, no family history of hypertension, diabetes, stroke or cardiac disease in first-degree relatives before the age of 70 years and have an average (two measurements) blood pressure of <130/89 mm Hg and >100/50 mmHg at the screening visit.
- •All subjects will have body mass index 19-25 kg/m
- •Subjects must have normal laboratory values for: Complete blood count; serum creatinine, sodium, potassium, glucose, liver enzymes; urinalysis; negative urine HCG in women; normal ECG
Exclusion Criteria
- •Alcohol intake >12oz per week, as well as tobacco or recreational drug use.
- •Any subject with a history of coronary disease, diabetes, hypertension, stroke, kidney disease, or illness requiring overnight hospitalization in the past 6 months will be excluded from the study.
- •Subjects taking any prescription medications (with the exception of birth control pills) or herbal medications will be excluded.
- •Because of the unknown risk of infused angiotensin II in pregnancy, women who are pregnant will be excluded from study and all women will be screened for pregnancy by quantitative serum hCG measurement on the day of each CCI admission.
- •Women currently breastfeeding will also be excluded from the study.
Arms & Interventions
Placebo
Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
Intervention: Placebo (Drug)
Fludrocortisone
Subjects will receive 0.1 mg of fludrocortisone (Florinef) on one of three study days.
Intervention: Fludrocortisone (Drug)
Epleronone
Subjects will receive 100 mg of epleronone on one of three study days.
Intervention: Eplerenone (Drug)
Outcomes
Primary Outcomes
Serum aldosterone after angiotensin II infusion
Time Frame: 5 days
Aldosterone levels after 30 mins AngII infusion
Secondary Outcomes
- Serum cortisol after angiotensin II infusion(5 days)
- Serum cortisol after cosyntropin infusion(5 days)
- Serum aldosterone after cosyntropin infusion(5 days)
Investigators
Gordon H. Williams, MD
Principal Investigator
Brigham and Women's Hospital